EU approves new twice-yearly HIV prevention jab

euronews.com

The European Commission has approved a new twice-yearly injection for HIV prevention, offering a significant advancement in combating the virus. This groundbreaking jab, lenacapavir (Yeytuo), has shown 100% effectiveness in preventing HIV in clinical trials, marking a major medical breakthrough. It will replace the need for daily pills. The approval follows a rise in HIV cases across Europe, with over 24,700 new diagnoses in 2023. The drug is also approved in the US and recommended by the WHO.


With a significance score of 6.4, this news ranks in the top 0.1% of today's 27764 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: